International Journal of Drug Policy
Volume 18, Issue 4 , Pages 329-332 , August 2007

Case study: Accessible primary health care—A foundation to improve health outcomes for people who inject drugs

Received 13 June 2006 ,Revised 25 September 2006 ,Accepted 13 November 2006.

References 

  1. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18(17):2295–2303
  2. Amin J, Law MG, Micaleff J, Jauncey M, van Beek I, Kaldor JM, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiology and Infection. May 2006;17:1–7
  3. Batalla J, Gatell J, Cayla JA, Plasencia A, Jansa JM, Parellada N. Predictors of the survival of AIDS in Barcelona, Spain. AIDS. 1989;3:355–359
  4. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS. 2006;20:783–784
  5. Buning EC. The role of harm reduction programmes in curbing the spread of HIV by drug injectors. AIDS and drug misuse. London: Routledge; 1990;pp. 153–161
  6. Buning EC, Coutinho RA, van Brussell GHA, van Santen G, van Zadelhoff AW. (Letter to the editor). Preventing AIDS in drug addicts in Amsterdam. Lancet. 1986;1:1435
  7. Clarke SM, Mulcahy FM. Anti-retroviral therapy for drug users. International Journal of STD & AIDS. 2000;11:627–631
  8. Crofts N, Jolley D, Kaldor JM, van Beek I, Wodak A. The epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health. 1997;51(6):692–697
  9. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. The New England Journal of Medicine. 1969;280:1372–1375
  10. Freeman T, Ffrench R, Post J, Harvey C, Gilmour S, White P, et al. Prevalence of production of virus-specific Interferon among seronegative hepatitis C-resistant subjects reporting injection drug use. The Journal of Infectious Diseases. 2004;190(6):1093–1097
  11. Freeman AJ, Zekry A, Whybin R, Harvey CE, van Beek I, Dekantzow SL, et al. Hepatitis C virus prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. The Medical Journal of Australia. 2000;172(12):588–591
  12. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. Journal of Acquired Immunodeficiency Syndrome. 1991;4:144–153
  13. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: A review. The Mount Sinai Journal of Medicine. 2000;67:429–436
  14. Jauncey M, Gilmour S, Micallef J, Amin J, White P, Rawlinson W, et al. Viral clearance in newly acquired hepatitis C infection among a cohort of injecting drug users, Sydney 1992–2002. The Journal of Infectious Diseases. 2004;190(7):1270–1274
  15. MacDonald, V., Dore, G., Amin, J., & van Beek, I. (in press). Predictors of completion of hepatitis B vaccination schedule in attendees at a primary health care facility. Sexual Health.
  16. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases. 2003;37(4):476–482
  17. Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: Results from the ALIVE and ISS studies. AIDS link to intravenous experiences. Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology. 1999;20(3):275–282
  18. Stott NCH. Primary health care: Bridging the gap between theory and practice. Berlin: Springer-Verlag; 1983;
  19. United Nations Office on Drugs and Crime. (2003). Investing in drug abuse treatment: A discussion paper for policy makers. Retrieved November 10, 2006 from http://www.unodc.org/pdf/report_2003-01-31_1.pdf.
  20. USA Department of Health and Human Services. (2006). Guidelines for the use of anti-retroviral agents in HIV-1-infected adults and adolescents. Retrieved September 4, 2006 from www.ashm.org.au/aust-guidelines.
  21. Van Beek I. Injecting drug users. Scaling up anti-retroviral therapy in resource-limited settings: Guidelines for a public health approach. World Health Organization; 2002;pp. 76–79
  22. Van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor JM. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourinary Medicine. 1994;70(5):321–324
  23. Van Beek I, Dwyer R, Dore G, Luo K, Kaldor J. Infection with HIV and hepatitis C among injecting drug users in Sydney in a prevention setting: Retrospective cohort study. British Medical Journal. 1998;317(7156):433–437
  24. Ward J, Mattick RP, Hall W. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998;
  25. WHO/UNAIDS. (March 2006). Progress on global access to HIV anti-retroviral therapy: A report on “3 by 5” and beyond.

PII: S0955-3959(06)00233-7

doi: 10.1016/j.drugpo.2006.11.005

International Journal of Drug Policy
Volume 18, Issue 4 , Pages 329-332 , August 2007

Article Tools